Weaning Ropinirole 1mg
Ropinirole should be discontinued gradually over a 7-day period, with the frequency reduced from 3 times daily to twice daily for 4 days, then to once daily for the remaining 3 days before complete withdrawal. 1
Discontinuation Protocol
The FDA-approved tapering schedule is straightforward and evidence-based 1:
For Parkinson's Disease (if applicable):
- Days 1-4: Reduce from 3 times daily to twice daily dosing
- Days 5-7: Reduce to once daily dosing
- Day 8: Complete discontinuation
For Restless Legs Syndrome (if applicable):
The FDA label recommends gradual reduction of the daily dose but does not specify an exact schedule for RLS 1. However, given the patient is on 1mg (which could be 1mg once daily for RLS or part of a divided dose for Parkinson's), apply the same 7-day taper principle.
Clinical Context
If the patient is taking 1mg once daily for RLS: Consider reducing to 0.5mg for 3-4 days, then 0.25mg for 3 days before stopping. This mirrors the stepwise reduction principle while accounting for the lower total daily dose.
If the patient is taking 1mg as part of a divided dose (e.g., 1mg TID = 3mg/day total): Follow the frequency reduction schedule above, maintaining the 1mg dose but reducing administration frequency.
Critical Considerations
Why Gradual Withdrawal Matters:
- Abrupt discontinuation can cause withdrawal symptoms
- Dopamine agonist withdrawal syndrome can occur (though less common with ropinirole than ergot agonists)
- For Parkinson's patients, sudden cessation risks acute worsening of motor symptoms
Important Caveats:
The 2025 AASM guidelines suggest against standard use of ropinirole for RLS due to augmentation risk with long-term use 2. This makes proper discontinuation even more important, as the patient may have been on it inappropriately or may be experiencing augmentation (worsening of RLS symptoms).
Monitor for:
- Return of underlying symptoms (RLS or parkinsonian features)
- Withdrawal symptoms (anxiety, depression, fatigue, pain)
- Orthostatic hypotension resolution (ropinirole can cause OH 3)
Renal Impairment:
If the patient has end-stage renal disease on hemodialysis, the same tapering principles apply, though these patients were typically on lower maximum doses 1.
Alternative Approach if 7-Day Taper Not Tolerated:
If symptoms emerge during the standard 7-day taper, slow the reduction further—extend each step to 5-7 days rather than 3-4 days. However, the FDA-specified 7-day protocol should be attempted first as it balances safety with minimizing prolonged dopamine agonist exposure.